Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Halozyme Therapeutics, Inc. (HALO) vs Jazz Pharmaceuticals PLC (JAZZ)

Halozyme Therapeutics, Inc. and Jazz Pharmaceuticals PLC are both Biotechnology companies. Jazz Pharmaceuticals PLC is the larger, with a market value of $15.3B against $13.1B — 1.2× the size. Jazz Pharmaceuticals PLC trades at the lower P/E: 15.6× against 32.4×. Halozyme Therapeutics, Inc. grew revenue faster over the last twelve months: 41.2% against 12.6%. Halozyme Therapeutics, Inc. has the higher net margin (24.9% vs 20.5%) and the higher return on invested capital (18.1% vs 8.06%). Across the 22 metrics below, Halozyme Therapeutics, Inc. leads on 12 and Jazz Pharmaceuticals PLC on 10.

Valuation

Metric HALO JAZZ Biotechnology median
P/E 32.36 15.60 7.88
P/S 8.03 3.27 11.47
P/B 93.06 3.13 2.52
Price to free cash flow 16.57 10.62 21.16
EV/EBITDA 21.24 10.64 0.74
EV/Sales 9.18 3.74 10.73
Earnings yield 3.09% 6.41% (28.84%)
Free cash flow yield 6.04% 9.42% (23.03%)

Profitability

Metric HALO JAZZ Biotechnology median
Gross margin 82.42% 88.42% 65.16%
Operating margin 35.90% 19.49% 0.00%
Net margin 24.86% 20.45% 0.00%
Free cash flow margin 48.46% 30.79% 0.00%
Return on equity 173.67% 22.11% (57.72%)
Return on assets 17.86% 8.54% (49.22%)
Return on invested capital 18.13% 8.06% 0.00%

Growth

Metric HALO JAZZ Biotechnology median
Revenue growth (TTM) 41.15% 12.59% 5.64%
EPS growth (last fiscal year) (25.36%) (167.51%) —
Revenue growth, 5-year CAGR 39.16% 12.54% 8.40%
Net income growth, 5-year CAGR 19.68% 0.00% 0.00%

Health

Metric HALO JAZZ Biotechnology median
Debt to equity 14.95 0.91 0.00
Current ratio 2.71 1.78 4.73
Net debt to EBITDA 3.56 10.96 0.96

Dividend

Metric HALO JAZZ Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric HALO JAZZ Biotechnology median
Market cap 13.08b 15.34b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack